Moderna Downgraded To Neutral From Overweight At Piper Sandler

Piper Sandler analyst Edward Tenthoff downgraded Moderna to Neutral from Overweight with a price target of $445, up from $246, post the Q2 results.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.